Categories  |  Inventors

Technology Overview

OHSU # 2978 — SARS-CoV-2 single domain antibody (nanobody) for the treatment of COVID-19

Summary

Oregon Health & Science University researchers have developed a highly potent SARS-CoV-2 neutralizing antibody that is effective against multiple variants and is highly stable, which could make it easy to store and transport.

Technology Overview

Nanobodies are functional single-domain antibodies from camelid species that offer several therapeutic advantages over traditional monoclonal antibodies. These benefits include having a higher degree of stability and being roughly one-tenth the size of traditional antibodies, which allows for better tissue penetration and access to epitopes. Nanobodies also offer practical advantages of being more rapid to produce, lower in cost, and easier to engineer than monoclonal antibodies.

The laboratory of Dr. Fikadu Tafesse has developed a novel nanobody, with demonstrated effectiveness as a potential COVID-19 therapeutic.  In vitro testing of the nanobody has demonstrated:

  • An ability to bind the SARS-CoV-2 spike protein and block interactions with human ACE2.
  • Neutralizing effect on SARS-CoV-2 infection at nanomolar concentrations.
  • High stability and biological activity at high temperatures (50 °C) and following lyophilization and aerosolization.
  • Effective neutralization of multiple SARS-CoV-2 variants, including delta.

Together these factors point to a favorable potential therapeutic profile for this novel nanobody’s utility in the treatment of COVID-19. Research is ongoing to produce a synthetic nanobody library based on this lead-compound to allow for faster screening and deployment of SARS-CoV-2variant-specific biological therapeutics in the future.

Licensing Opportunity

This technology is available for licensing and co-development.

 

 

 

Inventors:

Categories: